5 results
Describe the electrocardiographic changes and areas of late myocardial activation encountered in PLN and PKP2 mutation carriers during ajmaline provocation and the relation of these differences to the development for early stages of arrhythmogenic…
Although electroconvulsive therapy (ECT) is an effective treatment for depression, preventing relapse after successful ECT remains a major challenge. In the PRASED-study we evaluate the effectiveness of three strategies to reduce relapse: an…
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in…
The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B).
The aim of this prospective single-arm phase II study is to evaluate the efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFRTKI (osimertinib or lazertinib), for patients with EGFR-mutant advanced NSCLC,…